Genecentric Therapeutics Closes $7.5 Million Series B1 Financing
11/08/21, 12:55 PM
Location
Money raised
$7.5 million
Industry
biotechnology
GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, today announced the closing of an oversubscribed Series B1 financing, which raised $7.5 million.
Company Info
Location
100 capitola drive
durham, north carolina, united states
Additional Info
GeneCentric is a precision oncology company transforming cancer diagnostics and genomic profiling through the power of gene expression. With a foundation built on over a decade of research into gene expression, including the PurIST® test (commercially available through Tempus), GeneCentric has pioneered ExpressCT™, a proprietary technology that enables gene expression inference directly from circulating tumor DNA (ctDNA). This innovation is embodied in the GenomicsNext™ platform, a multimodal liquid biopsy solution that simultaneously detects DNA alterations and inferred gene expression from a single blood sample.